Future Outlook of China Preclinical and Toxicology Outsourcing Market
Product Description
It has been well recognized in the global pharmaceutical industry that the R&D productivity of discovering a new medicine has been low. The high failure rate in various development stages has been the main factor that drives up the overall cost of drug discovery effort; whereas the severe toxicity and safety concerns have been the major causes of the high development failure. As all drug companies are vigorously controlling the R&D cost, the high failure rate has become a controlling factor for them to improve the efficiency and productivity of drug discovery and development. To reduce the overall cost of drug development, eliminating un-developable drug candidates and avoiding them being unnecessarily advanced to any late development stage have become critical to all drug companies. As such, all drug companies are now conducting extensive toxicology and safety pharmacology research for any drug candidates.
Although relatively young, the service capability of Chinese CROs in preclinical and toxicology research has been significantly improved in the recent years. As China possesses a number of advantages in preclinical and toxicology research, many drug companies are attracted by the significant benefits of conducting this type of research in the country.
To help these drug companies better understand the current state of this Chinese industry, the report “Future Outlook of China Preclinical and Toxicology Outsourcing Market” published by JZMed, Inc, a world renowned market research firm specialized in Chinese pharmaceutical industry, provides them with the unique insights into the current service capability and capacity of the Chinese preclinical and toxicology outsourcing industry.
The report revealed the current structural composition and the latest developments of the Chinese industry. By comparing the service capability and market size of the Chinese industry with its counterparts in the world, the report also provides a clear picture of where the Chinese industry currently stands in the global preclinical and toxicology outsourcing industry.
More importantly, by analyzing both growth drivers and resistors of the future development of the Chinese industry and the competitive landscape of the world preclinical and toxicology outsourcing industry, the report also provides the clear picture of the future development potential of this Chinese industry.
The report is a must-read book to all professionals in the industries of pharmaceutical, biotechnology, financial investment and outsourcing service that are interested in the China’s pharmaceutical outsourcing industry. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of pharmaceutical industry in their own countries.